Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2026-02-04 00:00:00 ET · period of report 2026-02-02 · accession 0001661887-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-02-04 | 2026-02-02 | AKBA | Grund Nicholas | Chief Commercial Off | S - Sale | $1.39 | -84.8K | 561.8K | -13% | -$117.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | S | D | 53,585 | $1.39 | 592,994 | D | — | — | (F2) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. (F1) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2025. |
| 2 | Common | Common Stock | 2026-02-02 | S | D | 31,244 | $1.39 | 561,750 | D | — | — | (F3) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. (F1) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2025. |